Entry Into a Definitive Material Agreement On January 23, 2026, Daxor Corporation (“we” or “us”) entered into a definitive securities purchase agreement with certain investors pursuant to which we issued and sold an aggregate of 765,958 registered shares of our common stock at $11.75 per share, through a registered direct offering, for net proceeds, after placement agent fees and expenses, of approximately $8,142,006. The closing took place on January 26, 2026. The shares of common stock offe…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 30, 2024, Nasdaq notified the company that due to the passing of Mr. James A. Lombard on October 17, 2023, the company no longer complied with Nasdaq’s audit committee requirement set forth in Listing Rule 5605. However, based on the information regarding the appointment of Caleb DesRosiers to the company’s audit committee, as reported to Nasdaq by the company, the Nasdaq Staff has dete…

Other Events On March 25, 2024 Daxor Corporation announced it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base. The press release issued is attached to t…

Other Events The purpose of this 8-K is to provide further specific information regarding the use of proceeds from its May 22, 2023 offering. On May 22 2023, Daxor Corporation (“the Company”) raised net proceeds of $3,555,532 through a public offering of 410,260 shares at $9.75 per share, as stated in the Securities and Exchange Commission (SEC) ( https://www.sec.gov/Archives/edgar/data/27367/000149315223018750/form497.htm#Ha_006 ). The offering documents cited next generation technology deve…

Other Events Daxor Corporation (the “ Company ”) is filing this Current Report on Form 8-K to provide additional information regarding the use of proceeds from its public offering on May 22, 2023. In the offering, the Company raised net proceeds of $3,555,532 through the issuance of 410,260 shares at $9.75 per share. More information regarding the offering is available in the Prospectus Supplement filed with the Securities and Exchange Commission under Rule 497 of the Securities Act on May 23…

Director — Caleb DesRosiers: Caleb DesRosiers was appointed to the Board of Directors.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On January 20, 2022, Daxor Corporation (the “ Company ”) announced plans to transfer the listing of the Company’s common stock from the NYSE American Exchange to the Nasdaq Stock Market. Until the Company has transferred its listing to the Nasdaq Stock Market, the Company’s shares will continue to trade on the NYSE American Exchange. A copy of the press release announcing the plan to transfer…

Director: Annual board election with new director appointments and retirements.

CFO — John Wilkens: John Wilkens resigned to take a position in the financial services industry.